Cargando…
Pyruvate Kinase M2 Expression: A Potential Metabolic Biomarker to Differentiate Endometrial Precancer and Cancer that is Associated with Poor Outcomes in Endometrial Carcinoma
Background: Pyruvate kinase M2 (PKM2) is a regulator of the processes of glycolysis and oxidative phosphorylation, but the roles that it plays in endometrial cancer remain largely unknown. This study evaluated the PKM2 expression in normal endometrium, endometrial hyperplasia, and endometrial carcin...
Autores principales: | Lai, Yu-Ju, Chou, Yu-Ching, Lin, Yi-Jia, Yu, Mu-Hsien, Ou, Yu-Che, Chu, Po-Wei, Wu, Chia-Chun, Wang, Yu-Chi, Chao, Tai-Kuang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6926947/ https://www.ncbi.nlm.nih.gov/pubmed/31756939 http://dx.doi.org/10.3390/ijerph16234589 |
Ejemplares similares
-
The combination of aldehyde dehydrogenase 1 (ALDH1) and CD44 is associated with poor outcomes in endometrial cancer
por: Huang, Hsin-Hui, et al.
Publicado: (2018) -
Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer
por: Chao, Tai-Kuang, et al.
Publicado: (2017) -
Detection of endometrial precancer by a targeted gynecologic cancer liquid biopsy
por: Martignetti, John A., et al.
Publicado: (2018) -
Urokinase-type Plasminogen Activator Resulting from Endometrial Carcinogenesis Enhances Tumor Invasion and Correlates with Poor Outcome of Endometrial Carcinoma Patients
por: Huang, Chia-Yen, et al.
Publicado: (2015) -
Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway
por: Wang, Yiying, et al.
Publicado: (2016)